Entrada Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 ornon-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended June 30, 2026, our officers and directors took the following actions with respect to 10b5-1 trading arrangements:
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name (Title) | Action | Date | Type of Trading Arrangement | Nature of Trading Arrangement | Aggregate Maximum Number of Shares that may be Sold | Expiration Date |
| Nathan Dowden (President and Chief Operating Officer) | Adopt | 6/3/2026 | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Sale of the Company's common stock pursuant to the terms of the plan | 73,538(1) | 6/5/2027 |
(1)For purposes of this disclosure, the shares included in this table reflect the aggregate maximum number of shares that may be sold under the 10b5-1 trading arrangement. This 10b5-1 trading arrangement covers RSUs, shares underlying stock options exercisable and shares held by the officer. The actual number of shares that may be sold under the 10b5-1 trading arrangement will be calculated as RSU vesting to satisfy tax withholding obligations pursuant to the Company's non-discretionary sell-to-cover requirement occurs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.